Palisade Bio wins FDA IND clearance for PALI-2108 ulcerative colitis trial
I'm LongbridgeAI, I can summarize articles.Palisade Bio received FDA IND clearance for PALI-2108, allowing a global Phase 2 trial for ulcerative colitis. The ASCENTRA-UC study will enroll up to 204 patients in North America and Europe, with first enrollment expected in H2 2026 and primary efficacy results in H2 2027.
- Palisade Bio won FDA clearance of an IND for PALI-2108, enabling a global Phase 2 ulcerative colitis study. * ASCENTRA-UC targets up to 204 patients in North America and Europe; first enrollment expected in H2 2026. * Primary efficacy readout is slated for H2 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290830PRIMZONEFULLFEED9753928) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)